Paper34200522
Treatment or Prophylaxis against Hepatitis B Virus Infection in Patients with Rheumatic Disease Undergoing Immunosuppressive Therapy: An Update.
Stasi C and 3 others. J Clin Med, 2021. Cited by 5 papers, by iCite.
Cite this record
ConductScience Library. Treatment or Prophylaxis against Hepatitis B Virus Infection in Patients with Rheumatic Disease Undergoing Immunosuppressive Therapy: An Update. Papers, record 34200522. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34200522
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Treatment or Prophylaxis against Hepatitis B Virus Infection in Patients with Rheumatic Disease Undergoing Immunosuppressive Therapy: An Update.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References51
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28516869 | Recommendations for infectious disease screening in migrants to Western Europe with inflammatory arthropathies before starting biologic agents. Results from a multidisciplinary task force of four European societies (SIR, SER, SIMET, SEMTSI) facing the largest impact of the flow of migrants today. | Clin Exp Rheumatol | 2017 | https://conductscience.org/library/papers/28516869 | PubMed |
| 2 | 30932440 | Occult HBV infection may negatively impact on drug survival in patients with rheumatoid arthritis on treatment with a first biologic drug. An appraisal from the Biologic Apulian Registry (BIOPURE). | Reumatismo | 2019 | https://conductscience.org/library/papers/30932440 | PubMed |
| 3 | 33810942 | The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus-related hepatocellular carcinoma. | Eur J Intern Med | 2021 | https://conductscience.org/library/papers/33810942 | PubMed |
| 4 | 25447850 | American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. | Gastroenterology | 2015 | https://conductscience.org/library/papers/25447850 | PubMed |
| 5 | 28140087 | Rituximab: Mechanism of action and resistance. | Semin Oncol | 2002 | https://conductscience.org/library/papers/28140087 | PubMed |
| 6 | 18715666 | Statements from the Taormina expert meeting on occult hepatitis B virus infection. | J Hepatol | 2008 | https://conductscience.org/library/papers/18715666 | PubMed |
| 7 | 29720221 | Deleterious role of hepatitis B virus infection in therapeutic response among patients with rheumatoid arthritis in a clinical practice setting: a case-control study. | Arthritis Res Ther | 2018 | https://conductscience.org/library/papers/29720221 | PubMed |
| 8 | 28160426 | Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation. | Int J Rheum Dis | 2017 | https://conductscience.org/library/papers/28160426 | PubMed |
| 9 | 28011918 | Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Biologics Treatment. | J Infect Dis | 2017 | https://conductscience.org/library/papers/28011918 | PubMed |
| 10 | 29256314 | Hepatitis B virus reactivation in patients with rheumatoid arthritis: A single-center study. | Mod Rheumatol | 2018 | https://conductscience.org/library/papers/29256314 | PubMed |
| 11 | 29405329 | Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. | Hepatology | 2018 | https://conductscience.org/library/papers/29405329 | PubMed |
| 12 | 26879359 | Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study. | J Rheumatol | 2016 | https://conductscience.org/library/papers/26879359 | PubMed |
| 13 | 29611409 | Safety of Tocilizumab in Rheumatoid Arthritis Patients with Resolved Hepatitis B Virus Infection: Data from Real-World Experience. | Yonsei Med J | 2018 | https://conductscience.org/library/papers/29611409 | PubMed |
| 14 | 28320050 | Practice Pattern of Hepatitis B Testing in Rheumatoid Arthritis Patients: A Cross-National Comparison Between the US and Taiwan. | Arthritis Care Res (Hoboken) | 2018 | https://conductscience.org/library/papers/28320050 | PubMed |
| 15 | 29223453 | HBV reactivation in rheumatic diseases patients under therapy: A meta-analysis. | Microb Pathog | 2018 | https://conductscience.org/library/papers/29223453 | PubMed |
| 16 | 33161563 | Development of JAK inhibitors for the treatment of immune-mediated diseases: kinase-targeted inhibitors and pseudokinase-targeted inhibitors. | Arch Pharm Res | 2020 | https://conductscience.org/library/papers/33161563 | PubMed |
| 17 | 28529116 | Italian consensus Guidelines for the management of hepatitis B virus infections in patients with rheumatoid arthritis. | Joint Bone Spine | 2017 | https://conductscience.org/library/papers/28529116 | PubMed |
| 18 | 31550363 | Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral Therapy. | J Infect Dis | 2020 | https://conductscience.org/library/papers/31550363 | PubMed |
| 19 | 32051458 | Moderate Risk of Hepatitis B Virus Reactivation in HBsAg-/HBcAb+ Carriers Receiving Rituximab for Rheumatoid Arthritis. | Sci Rep | 2020 | https://conductscience.org/library/papers/32051458 | PubMed |
| 20 | 31779676 | Risk stratification and clinical course of hepatitis B virus reactivation in rheumatoid arthritis patients with resolved infection: final report of a multicenter prospective observational study at Japanese Red Cross Hospital. | Arthritis Res Ther | 2019 | https://conductscience.org/library/papers/31779676 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 39155780 | Hepatitis B virus infection, infertility, and assisted reproduction. | J Zhejiang Univ Sci B | 2024 | https://conductscience.org/library/papers/39155780 |
Source PubMed
Genes12
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/34200522
GET https://conductscience.org/api/papers/v1/34200522/references?page=2